Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Operating Expenses (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Operating Expenses for 6 consecutive years, with $32.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 20.9% to $32.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $102.1 million, a 42.2% decrease, with the full-year FY2025 number at $159.5 million, down 9.69% from a year prior.
  • Operating Expenses was $32.4 million for Q4 2025 at Caribou Biosciences, up from $31.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $48.4 million in Q1 2024 to a low of $14.8 million in Q1 2021.
  • A 5-year average of $33.0 million and a median of $34.3 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 139.66% in 2021, then dropped 21.52% in 2025.
  • Caribou Biosciences' Operating Expenses stood at $23.0 million in 2021, then surged by 49.23% to $34.3 million in 2022, then grew by 19.64% to $41.0 million in 2023, then decreased by 0.12% to $41.0 million in 2024, then dropped by 20.9% to $32.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Operating Expenses are $32.4 million (Q4 2025), $31.6 million (Q3 2025), and $38.1 million (Q2 2025).